Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

1 Beaten-Down Stock That Has a Lot to Prove in 2023

TheMotleyFool

0 0

1 Beaten-Down Stock That Has a Lot to Prove in 2023: https://g.foolcdn.com/editorial/images/719142/patient-sitting-on-hospital-bed.jpg

The past several years have been brutal for biotech company Bluebird bio (NASDAQ: BLUE). Shares of the gene-editing specialist are down by 85% since early 2020 as it has had to deal with clinical and regulatory setbacks, not to mention the marketwide headwinds that have impacted all equities.

However, last year may have been the turning point for Bluebird as the company earned important approvals for two gene-editing therapies in the U.S. The biotech still has some work to do, and the next few quarters will tell us more about its prospects. Let's see what could make Bluebird a solid contrarian buy this year.